Search

Search Constraints

You searched for: Author/Creator Fine, Gregg

Search Results

1. Abstracts from the 5th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 19–20 September 2014. Issue 5 (May 2015)

2. Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A. (6th November 2014)

3. Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab. Issue 2 (February 2019)

4. FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study. Issue 2 (1st February 2017)

5. Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1. (7th November 2013)

6. Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer. (6th November 2014)

7. Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. (December 2018)